MX388073B - Composición farmacéutica, preparación y usos de la misma. - Google Patents
Composición farmacéutica, preparación y usos de la misma.Info
- Publication number
- MX388073B MX388073B MX2017006812A MX2017006812A MX388073B MX 388073 B MX388073 B MX 388073B MX 2017006812 A MX2017006812 A MX 2017006812A MX 2017006812 A MX2017006812 A MX 2017006812A MX 388073 B MX388073 B MX 388073B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compound
- carrier
- biocompatible nanoparticle
- subject
- need
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende una combinación de al menos una nanopartícula biocompatible y de al menos un portador integrado de al menos un compuesto farmacéutico a ser administrado a un sujeto necesitado de dicho compuesto farmacéutico, donde la combinación de al menos una nanopartícula biocompatible y al menos un portador integrado de un compuesto farmacéutico potencializa la eficiencia de interés del compuesto. La dimensión más larga de la nanopartícula biocompatible está típicamente entre 4 y 500 Nm y su valor absoluto de carga de la superficie es de al menos 10Mv (10 m V). El portador, adicionalmente, carece de cualquier agente de superficie estéricamente estabilizada. La invención también se relaciona a dicha composición para uso en la administración de compuesto(s) del mismo, donde al menos una nanopartícula biocompatible y al menos un portador integrado de al menos un compuesto farmacéutico serán administrados separadamente a un sujeto necesitado de dicho compuesto farmacéutico, típicamente entre más de 5 minutos y 72 horas uno de otro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306875 | 2014-11-25 | ||
| PCT/EP2015/077425 WO2016083333A1 (en) | 2014-11-25 | 2015-11-24 | Pharmaceutical composition, preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017006812A MX2017006812A (es) | 2018-02-12 |
| MX388073B true MX388073B (es) | 2025-03-19 |
Family
ID=52013982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006812A MX388073B (es) | 2014-11-25 | 2015-11-24 | Composición farmacéutica, preparación y usos de la misma. |
| MX2021010595A MX2021010595A (es) | 2014-11-25 | 2017-05-24 | Composicion farmaceutica, preparacion y usos de la misma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010595A MX2021010595A (es) | 2014-11-25 | 2017-05-24 | Composicion farmaceutica, preparacion y usos de la misma. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10765632B2 (es) |
| EP (2) | EP3236934B1 (es) |
| JP (1) | JP6789960B2 (es) |
| KR (1) | KR102666251B1 (es) |
| CN (1) | CN107106703A (es) |
| AR (1) | AR102782A1 (es) |
| AU (1) | AU2015352685B2 (es) |
| BR (1) | BR112017010953B1 (es) |
| CA (1) | CA2968919C (es) |
| DK (1) | DK3236934T3 (es) |
| EA (1) | EA201791147A1 (es) |
| ES (1) | ES2982895T3 (es) |
| FI (1) | FI3236934T3 (es) |
| HU (1) | HUE067642T2 (es) |
| IL (2) | IL290114B2 (es) |
| LT (1) | LT3236934T (es) |
| MX (2) | MX388073B (es) |
| NZ (1) | NZ769187A (es) |
| PL (1) | PL3236934T3 (es) |
| PT (1) | PT3236934T (es) |
| SG (1) | SG11201704219UA (es) |
| TW (1) | TW201628656A (es) |
| UA (1) | UA123665C2 (es) |
| WO (1) | WO2016083333A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10413509B2 (en) | 2013-05-30 | 2019-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| TW201628610A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| US20170258937A1 (en) | 2014-11-25 | 2017-09-14 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PL3229776T3 (pl) | 2014-11-25 | 2023-11-06 | Curadigm Sas | Kompozycja farmaceutyczna łącząca co najmniej dwie różne nanocząstki i związek farmaceutyczny, jej wytwarzanie i zastosowanie |
| US11096962B2 (en) | 2015-05-28 | 2021-08-24 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
| WO2025088597A1 (en) * | 2023-10-26 | 2025-05-01 | New Phase Ltd. | Nanoparticle combination therapy for tumors |
| WO2025116176A1 (ko) * | 2023-11-30 | 2025-06-05 | 엔바이오셀 주식회사 | 나노입자 |
| CN119280158A (zh) * | 2024-10-14 | 2025-01-10 | 四川大学 | 一种基于聚磺酸甜菜碱的环刷状聚合物载药胶束的制备及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| ATE453381T1 (de) * | 2002-12-31 | 2010-01-15 | Bharat Serums & Vaccines Ltd | Nicht-pegylierte lang-zirkulierende liposome |
| US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| JP5513708B2 (ja) * | 2003-12-22 | 2014-06-04 | ブラッコ・シュイス・ソシエテ・アノニム | 造影イメージング用の気体封入マイクロベシクル・アセンブリー |
| US20080193372A1 (en) * | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| US20060264804A1 (en) * | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| US20070088414A1 (en) * | 2005-05-25 | 2007-04-19 | Campbell Robert L | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| US20090130050A1 (en) * | 2006-03-24 | 2009-05-21 | Toto Ltd. | Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them |
| US20100233219A1 (en) | 2006-03-30 | 2010-09-16 | Fujifilm Corporation | Inorganic nanoparticle compromising an active substance immobilized on the surface and a polymer |
| CA2649870C (en) | 2006-05-04 | 2014-07-29 | University Of South Australia | Drug release from nanoparticle-coated capsules |
| BRPI0815613A2 (pt) * | 2007-08-21 | 2015-03-24 | Alza Corp | Composições lipossômicas para administração in vivo de compostos de ácido borônico. |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| EP2231765A2 (en) | 2007-12-21 | 2010-09-29 | University Of Guelph | Polysaccharide nanoparticles |
| US9403789B2 (en) | 2008-02-21 | 2016-08-02 | Sequoia Pharmaceuticals, Inc. | Benzofuran-containing amino acid inhibitors of cytochrome P450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| WO2010048623A2 (en) | 2008-10-26 | 2010-04-29 | Board Of Regents, The University Of Texas Systems | Medical and imaging nanoclusters |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| WO2011102407A1 (ja) | 2010-02-17 | 2011-08-25 | 国立大学法人神戸大学 | 放射線治療剤 |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| JP5713311B2 (ja) * | 2010-09-24 | 2015-05-07 | 国立大学法人名古屋大学 | リポソーム複合体、その製造方法、及びその使用 |
| US9782342B2 (en) | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| JP2014503575A (ja) * | 2011-01-31 | 2014-02-13 | ナノビオティックス | 超常磁性のナノ粒子を用いて、興味対象生成物のリポソームからの放出をモニターする方法 |
| DK2670394T3 (en) | 2011-01-31 | 2019-01-14 | Nanobiotix | NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND APPLICATIONS THEREOF |
| US10251841B2 (en) | 2011-10-17 | 2019-04-09 | Trustees Of Boston University | Polymeric depots for localization of agent to biological sites |
| US20150209397A1 (en) | 2012-09-07 | 2015-07-30 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US10413509B2 (en) * | 2013-05-30 | 2019-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| TW201628610A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| PL3229776T3 (pl) * | 2014-11-25 | 2023-11-06 | Curadigm Sas | Kompozycja farmaceutyczna łącząca co najmniej dwie różne nanocząstki i związek farmaceutyczny, jej wytwarzanie i zastosowanie |
| BR112017010933A2 (pt) | 2014-11-25 | 2018-02-14 | Nanobiotix | composição farmacêutica |
| US20170258937A1 (en) | 2014-11-25 | 2017-09-14 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
-
2015
- 2015-11-24 EP EP15798435.2A patent/EP3236934B1/en active Active
- 2015-11-24 CA CA2968919A patent/CA2968919C/en active Active
- 2015-11-24 MX MX2017006812A patent/MX388073B/es unknown
- 2015-11-24 ES ES15798435T patent/ES2982895T3/es active Active
- 2015-11-24 JP JP2017546031A patent/JP6789960B2/ja active Active
- 2015-11-24 PT PT157984352T patent/PT3236934T/pt unknown
- 2015-11-24 SG SG11201704219UA patent/SG11201704219UA/en unknown
- 2015-11-24 KR KR1020177017322A patent/KR102666251B1/ko active Active
- 2015-11-24 BR BR112017010953-0A patent/BR112017010953B1/pt active IP Right Grant
- 2015-11-24 AU AU2015352685A patent/AU2015352685B2/en active Active
- 2015-11-24 EP EP24176220.2A patent/EP4431155A3/en active Pending
- 2015-11-24 WO PCT/EP2015/077425 patent/WO2016083333A1/en not_active Ceased
- 2015-11-24 IL IL290114A patent/IL290114B2/en unknown
- 2015-11-24 LT LTEPPCT/EP2015/077425T patent/LT3236934T/lt unknown
- 2015-11-24 US US15/529,106 patent/US10765632B2/en active Active
- 2015-11-24 FI FIEP15798435.2T patent/FI3236934T3/fi active
- 2015-11-24 TW TW104139006A patent/TW201628656A/zh unknown
- 2015-11-24 EA EA201791147A patent/EA201791147A1/ru unknown
- 2015-11-24 HU HUE15798435A patent/HUE067642T2/hu unknown
- 2015-11-24 NZ NZ769187A patent/NZ769187A/en unknown
- 2015-11-24 UA UAA201706347A patent/UA123665C2/uk unknown
- 2015-11-24 AR ARP150103850A patent/AR102782A1/es unknown
- 2015-11-24 CN CN201580071112.9A patent/CN107106703A/zh active Pending
- 2015-11-24 PL PL15798435.2T patent/PL3236934T3/pl unknown
- 2015-11-24 DK DK15798435.2T patent/DK3236934T3/da active
-
2017
- 2017-05-23 IL IL252462A patent/IL252462B/en unknown
- 2017-05-24 MX MX2021010595A patent/MX2021010595A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| NZ714273A (en) | Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof | |
| MX2016005668A (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
| WO2017042607A3 (en) | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain | |
| MX2017006813A (es) | Composicion farmaceutica, preparacion y usos de la misma. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX394658B (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| MX378155B (es) | Derivados de 9h-pirrolo-dipiridina. | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EP4553065A3 (en) | Novel compounds for treating mitochondrial disease | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| MY173573A (en) | Pyridin-4-yl derivatives | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| AR102780A1 (es) | Composiciones farmacéuticas, su preparación y sus usos | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| MX386107B (es) | Composiciones para el cuidado bucal. | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX2015011588A (es) | Tratamiento de combinacion. | |
| TR201905694T4 (tr) | Aripiprazol ön ilaç bileşimleri. |